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Abstract
Background: Glioblastoma multiforme (GBM) cells secrete large amounts of glutamate that can trigger AMPA-type
glutamate receptors (AMPARs). This commonly results in Na
+ and Ca
2+-permeability and thereby in excitotoxic cell death of
the surrounding neurons. Here we investigated how the GBM cells themselves survive in a glutamate-rich environment.
Methods and Findings: In silico analysis of published reports shows down-regulation of all ionotropic glutamate receptors
in GBM as compared to normal brain. In vitro, in all GBM samples tested, mRNA expression of AMPAR subunit GluR1, 2 and 4
was relatively low compared to adult and fetal total brain mRNA and adult cerebellum mRNA. These findings were in line
with primary GBM samples, in which protein expression patterns were down-regulated as compared to the normal tissue.
Furthermore, mislocalized expression of these receptors was found. Sequence analysis of GluR2 RNA in primary and
established GBM cell lines showed that the GluR2 subunit was found to be partly unedited.
Conclusions: Together with the lack of functional effect of AMPAR inhibition by NBQX our results suggest that down-
regulation and afunctionality of AMPARs, enable GBM cells to survive in a high glutamate environment without going into
excitotoxic cell death themselves. It can be speculated that specific AMPA receptor inhibitors may protect normal neurons
against the high glutamate microenvironment of GBM tumors.
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Introduction
High-grade gliomas (glioblastoma multiforme (GBM)) are the
most common aggressive malignant brain tumors. Despite new
diagnostic techniques and combined modality therapy [1],
prognosis remains dismal. GBMs are highly angiogenic and show
patterns of invasive growth throughout the brain, making radical
surgery impossible and leading in almost all cases to tumor
recurrence [2]. Several autocrine and paracrine factors are
thought to contribute to the invasive and migratory properties of
GBM cells, interacting with the microenvironment and enhancing
motility and invasion [3]. Glutamate, one of the major
neurotransmitters in the central nervous system, and its metabo-
lism via receptors and transporters, is thought to be a contributing
factor to the malignant behavior of GBM [4,5]. Glutamate binds
to both ligand gated ion channels - NMDA (N-methyl-D-apertate),
AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid),
kainate receptors - and metabotropic glutamate receptors [6].
Intracellular signaling is thought to be initiated upon glutamate-
induced modulation of the ion channels in GBM cells [7,8] as well
as in surrounding astrocytes, neurons, pericytes, and endothelial
cells [9–13]. Specific inhibitors of these receptor channels are
therefore thought to exert anti-tumor effects on GBM cells [5].
Down-regulation of astrocytic glutamate transporters and
upregulation of the cystine-glutamate antiporter system (system
xc
2) in GBM cells results in high concentrations of glutamate in
the microenvironment. Glutamate abundance is consequently
thought to lead to excitotoxic cell-death of neurons, mainly via the
neuronal NMDA receptor, but also via AMPA and kainate
receptor overstimulation [9,10,14].
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5953Glioma cells are able to regulate calcium conductance by
modifying AMPAR subunit-expression (GluR1-4). AMPAR GluR2
subunit transcripts are subjected to RNA Q/R editing, causing
receptor impermeability[15]. Interestingly, Labrakakis et al. report-
ed that ionotropic GluR activation by glutamate depolarized only a
fraction of the GBM cells without showing typical NMDA or non-
NMDA currents [16]. Upon modification of GBM cells by viral
vector-mediated restoration of the GluR2 subunit, GBM cells failed
to form tumors in the brain of nude mice, indicating a pro-survival
role for GluR2 down-regulation in GBM [4]. Yoshioka et al.
described that human neuroblastoma and medulloblastoma cells
failed to assemble Ca
2+-permeable channels, despite expressing a
variety of non-NMDA and NMDA receptor genes. This failure
confers protection against excitotoxicity and may contribute to
progression of tumors of these types [17].
Here, we analyzed AMPA receptor expression and subunit
configuration in GBM cells. A decreased ionotropic glutamate
receptor, including AMPAR, expression was shown in an in silico
analysis of primary GBM samples, compared to normal non-
neoplastic brain and low-grade gliomas. Our results show down-
regulated protein and mRNAexpression inGBM cells,from patient
materialandestablishedcelllinesascomparedtonormalbraincells.
We furthermore show partial GluR2 posttranscriptional RNA
under-editing in primary brain tumor cells. AMPA receptor
blockage with NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]-
quinoxaline-2,3-dione) , a potent competitive AMPA receptor
antagonist, conveyed no effect on cell proliferation. These results
suggest that down-regulation of functional AMPAR expression is a
mechanism allowing GBM cells to escape excitotoxic cell death.
Results
In silico analysis of AMPAR expression in GBM patients
In order to determine whether AMPAR subunits are expressed in
GBM, we performed in silico analysis using Oncomine [18],
comparing mRNA expression profiles in dataset of 77 GBMs with
23 samples of non-neoplastic control brain tissue [19] (Figure 1A). An
overall down-regulation of ionotropic receptor expression - NMDA
(NR1, NR2A–C, NR3A), AMPA (GluR1–4) and kainate (GluR5,7;
KA2) receptor - was observed between the controls and the GBM
patients,which wasstatistically significant ascalculated by Student’st-
test (p,0.0001).Nostatisticallysignificantdifferencewasobservedfor
GluR7 and KA1. All receptors except for GluR6 showed down-
regulation compared to the non-neoplastic control. The largest effect
was observed for NMDA receptor NR3A, NR1 and AMPA receptor
GluR2, with t-values of 14.665; 10.914 and 8.940, respectively (Table
S1). In order to determine whether AMPAR expression correlated
with tumor grading AMPAR expression values from low-grade
gliomas (WHO grade II oligodendrogliomas and astrocytomas) were
compared to the expression values in GBMs (WHO grade IV).
AMPA receptor expression was negatively correlated to tumor
grading, i.e. oligodendrogliomas and astrocytomas showed higher
expressionofAMPARsascomparedtotheGBMsamples(Figure1B).
No difference in ionotropic glutamate receptor expression was seen
between WHO grade II astrocytomas and oligodendrogliomas
(Figure S1).
Protein expression
To validate AMPAR protein expression in GBM, immunohis-
tochemistry on GluR1 and 2 was performed on 37 paraffin
embedded tumor sections of GBM. The multiform phenotype of
GBM, with a large variety of different cell types (tumor cells, stem
cells, fibroblasts, microglia and endothelial cells), complicates
discerning immunostaining of actual tumor cells. A GBM tissue
microarray was created with paraffin cores enriched for tumor
cells as assessed by two independent neuropathologists. Cell lines
of GBM were stained to further substantiate AMPA receptor
immunoreactivity in tumor cells.
No overexpression of AMPARs was observed in these tumor
sections, as compared to normal brain tissues cerebellum and
hippocampus, in which more abundant and intensive staining was
observed (Figure 2A, a–d). Large variation of GluR1 protein
expression was observed between patients. Within tumor sections
concordance of staining of the different cores allowed for semi-
quantitative scoring. Predominantly, cytoplasmatic staining was
observed, providing evidence of receptor mislocalization. Only 14%
of the cases showed GluR1 expression in more than 60% of the
tumor cells (Figure 2B). GluR2 protein expression was also variable
between patients and, to a lesser extent within the individual tumor
sections, allowing semi-quantitative scoring. GluR2 was mainly
localized to the plasma membrane. Expression of GluR2 was higher
than GluR1 expression, 36% of the samples showed GluR2
expression in more than 60% of the tumor cells (Figure 2B). In
addition, in 9 GBM sections nuclear staining was observed using an
antibody directed against GluR2/4 (data not shown).
On cytospin slides of primary VU-122 GBM cells and the U87-
MG cell line, membranous staining of GluR2 was observed
(Figure 2A, f), whereas in primary VU-028 GBM cells cytoplas-
matic GluR2 expression was seen. Chamber slide stainings of VU-
028, VU-122 and U87-MG cells also showed GluR2 nuclear and
cytoplasmatic localization (Figure 2A, e), again indicative of
receptor mislocalization. In summary, GBMs show relatively low
but variable GluR1, 2 and 2/4 expression, which is often not
localized on the cell membrane.
GluR mRNA expression and editing in GBM cells
In order to ascertain mRNA expression, RT-PCR for GluR1, 2
and 4 mRNA expression was performed using 2 primary GBM
lines and the established U87-MG GBM cell line (Figure 3A).
None of the cell lines showed mRNA overexpression for these
GluR subunits compared to adult and fetal total brain mRNA and
adult cerebellum mRNA. The cell lines had a variable expression
for GluR1 and 2. In addition, GluR4 expression was measured in
all cell lines, except for VU-028 and U87-MG, which showed
weak expression (Figure 3A). In order to determine whether
GluR2 was edited, the RNA was sequenced of the GBM cells,
adult brain, fetal brain and adult cerebellum (Figure 3B). Adult
cerebellum, adult brain and fetal brain expressed fully edited
GluR2 subunit mRNA, no unedited GluR2Q was detected.
Unedited GluR2Q was detected in part of the primary VU-028
and VU-122 GBM cells.
Role of ion channel functionality in cell proliferation
To further elucidate the role of ion channel functionality, GBM
cells were exposed to increasing concentrations of the competitive
AMPAR antagonist NBQX and the effect on in vitro cell growth
was monitored.
No significant growth inhibition was observed upon AMPAR
inhibition, using NBQX concentrations that completely block
AMPA and kainate receptors (Ki values of 0.1–0.9 mM and 15.8–
19.8 mM, respectively) (Figure 4). These functional experiments
indicate that the ion channel function of these AMPAR receptors
is not essential for GBM cell proliferation in vitro.
Discussion
Many contradictory results have been published on the relevance
of glutamate triggering of AMPAR in GBM progression. Therefore,
AMPA Receptors in Glioblastoma
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environment while the normal surrounding neural cells undergo
excitotoxic cell death [9,10]. We show that down-regulation of
AMPAR expression and mislocalization of these receptors enables
the cells to survive in this neurotoxic environment. In addition, we
found no influence of these receptors in proliferation of the GBM
cells, since complete blocking of the electrophysiological function by
NBQX did not result in growth inhibition. To substantiate that these
receptors may not be functional in GBM we performed several pilot
experiments where the glutamate induced currents were measured
using whole cell voltage clamped measurements.In all GBM cell lines
tested (e.g. VU-028, VU-78, VU-119, VU-121, VU-122, VU-147,
VU-154 and U87-MG) we could not detect any proper current
response (Figure S2). Due to these negative results in all cells
measured so far (.100 cells) at two different laboratories these
experiments were not pursued. To fully prove this lack of ion channel
function, a more thorough study is warranted including fresh tumor
slices. Our results however again suggest lack of AMPAR function in
the GBM cells.
Our findings regarding the down-regulated expression of
AMPAR are supported by in silico analyses that show down-
regulated mRNA expression of all ionotropic (NMDA- and non-
Figure 1. In silico analysis of ionotropic glutamate receptor expression levels in GBM tumors. (A) Boxplots of expression of ionotropic
glutamate receptors in a dataset of 77 glioblastomas (grey dashed), compared to normal brain from epilepsy surgery (white). p-values and t-test
values shown in Table S1. (B) Compared to normal brain (white), low grade astrocytoma and oligodendroglioma (n=76, grey), AMPA receptor
(GRIA1–4) expression is decreased in GBM (n=77, grey dashed) (p,0.0001). Error bars indicate the standard deviation.
doi:10.1371/journal.pone.0005953.g001
AMPA Receptors in Glioblastoma
PLoS ONE | www.plosone.org 3 June 2009 | Volume 4 | Issue 6 | e5953Figure 2. AMPAR immunohistochemistry on paraffin embedded sections. (A) Representative images of (a) GluR1 in hippocampus, (b)
GluR1 in GBM, (c) GluR2 in cerebellum, (d) GluR2 in GBM, (e) GluR2 staining in chamberslide of VU-122 cell line, (f) GluR2 staining in cytospin of VU-
122. (B) Histogram of protein expression of GluR1 and GluR2 in 37 cases of adult GBM.
doi:10.1371/journal.pone.0005953.g002
AMPA Receptors in Glioblastoma
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receptors showed the highest degree of down-regulation in this
dataset, which could provide an additional mechanism of
excitotoxicity escape [20].
In summary, in this study we show that on protein level, AMPA-
type glutamate receptor subunits are variably expressed in GBM
and are overall down-regulated as compared to the normal brain
tissue. Besides low and mislocalized expression of AMPA receptors
we could not find evidence for ion channel functionality of GBM
cells by lack of any depolarization using patch-clamp recordings
and lack of growth inhibition after exposure to the AMPAR
inhibitor NBQX. These results suggest that stimulation of AMPA
receptors - and probably other ionotropic receptors - is not
required for GBM cell growth.
Mislocalization of glutamate receptors could be a result of
defective trafficking of these receptors. Several proteins are
involved in this process. Recently, transmembrane AMPAR
regulatory proteins (TARPs) were described to function in specific
Figure 3. AMPAR mRNA expression in GBM cell lines. (A) RT-PCR of GluR1, 2 and 4 mRNA expression on primary VU-028 and VU-122 GBM cells
and the established cell line U87-MG. (B) GluR2 PCR sequencing analysis. Posttransciptional RNA editing at the Q/R site in the second membrane
domain (M2) of the GluR2 subunit. The glutamine (Q) codon (CAG) is substituted by an arginine (R) codon (CGG) by replacement of a single
nucleotide, adenine to guanine, at position 2168. Adult and fetal brain, adult cerebellum, and glioblastoma cell line U87-MG express fully edited
GluR2R (CGG). VU-028 and VU-122 express a combination of both GluR2R and unedited GluR2Q (CAG) subunits.
doi:10.1371/journal.pone.0005953.g003
AMPA Receptors in Glioblastoma
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trafficking [21]. Strikingly, in silico analysis of TARPs showed
strong down-regulation of TARP c-2 and c-3 in GBM compared
to normal brain [22] (Figure S3), gaining further insight in possible
mechanisms of AMPAR mislocalization.
AMPA receptor antagonists were thought to be of potential use
as anti-cancer drugs in GBM[5]. Although failing to inhibit GBM
cell proliferation, it can be hypothesized that these drugs could still
be of potential use in conveying neuroprotection. Using specific
inhibitors excitotoxic AMPA and NMDA receptor mediated cell
death of neurons could be prevented [23,24].
Our data provide evidence of down-regulation of AMPAR
expression and function in GBM cells and show that these
receptors are not essential for the proliferation of these cells.
Down-regulation of ionotropic NMDA and non-NMDA gluta-
mate receptors in GBM might allow for the escape of glutamate-
mediated toxicity and might facilitate survival in a self-created
glutamate rich microenvironment. By imposing excitotoxic cell
death on normal neurons and not themselves, GBM cells may
manipulate their environment. Based on these findings we
speculate that normal neurons might be protected against the
high glutamate microenvironment by specific inhibitors of
ionotropic receptors [24,25], but further research is warranted.
Materials and Methods
In silico analysis
Oncomine [18], a compendium and data-mining application,
was used to analyze ionotropic glutamate receptor expression in a
transcriptome profile dataset of 77 glioblastoma multiforme
samples (WHO grade IV) compared to normal, non-neoplastic
brain tissue (n=23), astrocytoma (WHO grade II) (n=26) and
oligodendroglioma (WHO grade II) (n=50), as described in the
data by Sun et al. [19].
Patient samples
For immunohistochemistry, 37 cases of adult glioblastoma
multiforme were included. General written informed consent is
obtained from all patients for the use of tumor material. The
Cancer Center Amsterdam/VUmc Institute for Cancer and
Immunology scientific research committee approved this study.
All cases were reviewed independently by two neuropathologists
and the diagnosis of GBM was confirmed according to the revised
2007 WHO classification of tumors of the nervous system [26]. A
total of 28 cases of GBM were processed onto a tissue micro-array;
per patient 3 representative cores with a diameter of 0.6 mm were
isolated out of paraffin-embedded tissue. Both paraffin-embedded
GBM tissues (n=9) and the GBM tissue-array were used for
immunohistochemistry. As positive controls for immunohisto-
chemistry, post-mortem paraffin embedded tissue of adult
hippocampus and cerebellum were used. General written
informed consent is obtained from all patients for the use of
tumor material.
Cells and antibodies
Primary cell lines VU-028, VU-078, VU-119, VU-121, VU-
122, VU-147 and VU-154 were processed from fresh tumor tissue
obtained at surgery from patients with a primary GBM and
cultured in Dulbecco’s modification of Eagle’s medium (DMEM;
Flow Laboratories, Scotland) with 10% FCS (Invitrogen), and 1%
Glutamine (Invitrogen). Rabbit anti-human GluR1 monoclonal
antibody (clone E308) was obtained from Epitomics (Burlingame,
CA, USA), anti-Glutamate Receptor 2 monoclonal antibody
(MAB397 MsXGluR2, clone 6C4) and anti-glutamate receptor 2
& 4 monoclonal antibody (MAB396) were obtained from
Chemicon International (Temecula, CA, USA).
Immunohistochemistry and -cytochemistry
Tissue sections (5 mm) mounted on superfrost slides (Menzel,
Braunschweig, Germany) had undergone dewaxing and rehydra-
tion, after which endogenous peroxidase activity was blocked for
30 min in methanol containing 0.3% hydrogen peroxide. Slides
were then washed with distilled water and phosphate-buffered
saline (PBS; 10 mM, pH 7.4). For antigen retrieval, the slides were
placed in sodium citrate buffer (10 mM, pH 6.0) and heated in a
microwave oven at 99uC for 10 min, and cooled to room
Figure 4. Effect of AMPA receptor antagonist NBQX on proliferation of GBM cell lines. Surviving cells fractions after exposure of GBM cells
to different concentrations of the AMPA receptor antagonists NBQX. Shown are the averages of three experiments performed in triplicate. Error bars
indicate the standard deviation. Corresponding GluR mRNA subunit expression levels are indicated on the left.
doi:10.1371/journal.pone.0005953.g004
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with 10% normal goat serum (NGS) diluted in PBS 30 min prior
to incubation with GluR1 antibody (diluted 1:20) for 2 hr, or
GluR2 antibody (diluted 1:2000) for 1 hr, or GluR2/4 antibody
(diluted 1:200) for 1 hr. The sections were washed with PBS and
incubated at room temperature for 1 hr with the appropriate
biotinylated secondary antibody diluted in PBS. For the detection
of mouse antibodies Power Vision (ImmunoLogic, Duiven, the
Netherlands) was used according to the instructions of the
manufacturer. Peroxidase activity was detected using 3,3-diami-
nobenzidine-tetrachloride (Sigma, USA) in 0.1% hydrogen
peroxide. All sections were counterstained with haematoxylin
and mounted with an aqueous mounting medium (Kaiser’s
glycerol gelatin, Merck). Immunocytochemistry was performed
on cytospins and chamber slides. Cytospins were fixed in icecold
buffered formaldehyde-acetone. Chamberslides (Nunc/Thermo
Fisher Scientific, Breda, The Netherlands) were fixed using 2%
paraformaldehyde. Endogenous peroxidase activity was blocked
for 10 min in phosphate-buffered solution (PBS) containing 0.25%
hydrogen peroxide. The slides were incubated with the antibodies
and peroxidase activity was detected using 3,3-diaminobenzidine-
tetrachloride (Sigma, USA) in 0.1% hydrogen peroxide and
enhanced with 0.4% cupric sulfate. All sections were counter-
stained with haematoxylin.
Tissue sections were examined by two independent observers
with respect to the presence of neoplastic and/or non-malignant
tissue and specific immunoreactivity for the different AMPA
receptors of interest. Immunoreactivity was quantified on whole
cores of the tissue micro-array (0.6 mm in diameter) and 4
independent fields in whole tissue slides using a light microscope
with 256 magnification. Staining indices (number of stained
tumor cells per total number of tumor cells) were assigned semi-
quantitatively to five categories: ,20%, 20–39%, 40–59%, 60–
79%, .80%.
mRNA expression analysis
To semi-quantitatively assess GluR1, GluR2 and GluR4
mRNA expression in glioblastoma cell line (U87-MG) and
glioblastoma primary cell lines (VU-028 and VU-122), total
RNA was extracted using RNA Bee (Bio-connect BV, Huizen,
The Netherlands) according to the manufacturer’s instructions.
First-strand cDNAs were synthesized with reverse transcriptase by
using 1 mg of total RNA as a template and oligo-dT as primers.
GluR1, GluR2, GluR4 primer sequences were determined using
Oligo 6 software (Molecular Biology Insights, CO, USA). GluR1
(forward), 59-TTTGAGGAAGGACGGGACCA-39; GluR1 (re-
verse), 39-ATCGTTGGTGGCGTCTGGTG-59; GluR2 (for-
ward), 59-TCCTGGTCAGCAGATTTAG-39; GluR2 (reverse),
39-ATCGAAAGTGCTGAGGATC-59; GluR4 (forward), 59-
ACACAGAAGAGCCAGAGGACGGA-39; GluR4 (reverse), 39-
TGCCCTTGGATTTGCGGACAC-59; ß-actin primers were
used as described [27]. The amplified RT-PCR products were
analyzed on 1% agarose gels.
Sequence analysis of GluR2
Sequence analysis was performed using ABI 3130 system
(Applied Biosystems). For sequencing of the GluR2 PCR product,
samples were denaturated at 95uC for 3 min, amplified in 45
cycles (1 min of denaturation at 96uC, 15 sec of primer annealing
at 55uC, and 4 min of elongation at 60uC).
Whole-cell voltage clamp recordings
Whole cell voltage clamp recordings were performed as
described by Colquhoun et al. [28]. Measurements were performed
in two independent laboratories. Primary patient GBM cells (VU-
028, VU-78, VU-147, VU-154, VU-119, VU-121, VU-122) and
commercially available cell line U87-MG) were cultured on glass
coverslips. For recordings cells were transferred to a recording
chamber containing 126 mM NaCl, 3 mM KCl, 2 mM MgSO4,
2 mM CaCl2,1 0m MD ( +)-glucose, 1.2 mM NaH2PO4,2 6m M
NaHCO3 (carboxygenated with 5% CO2/95% O2). Whole-cell
recordings were made at room temperature (20–22uC), using 3–
4M V borosilicate glass electrodes, containing 77 mM K-gluco-
nate, 77 mM KCl, 0.5 EGTA, 10 mM HEPES, 4 mM Mg-ATP,
4 mM K2Phosphocreatine, 0.4 mM GTP (pH 7.3 with KOH).
Cells were voltage clamped at 270 mV, lifted from the glass
coverslip, and placed in front of a piezo-controlled (P 245.70,
Physik Instrumente, Waldbronn, Germany) fast application system
with a double-barreled application pipette. Reliability of applica-
tion was checked before experiments by measuring the open-tip
response to application of diluted (10%) extracellular solution.
Current responses were recorded upon 100 ms application of
glutamate (1000 mM) using an EPC-8 amplifier with PULSE
software (HEKA Elektronik, Lambrecht, Germany). Both primary
GBM cells (VU-028, VU-078, VU-121, VU-122, VU-147, VU-
157) and established GBM cell line U87-MG were measured
several times in this whole cell patch-clamp setup after glutamate
application. VU-78 cells were also recorded after AMPA (100 mM)
and kainate (100 mM) application. As a control, we tested
glutamate application on a nucleated patch pulled from a
neocortical pyramidal cell in an acute mouse brain slice.
Cytotoxicity cell proliferation assay
Proliferation of glioblastoma cell lines VU-122 and U87-MG,
growing in a monolayer, were determined using the sulphorho-
damine B (SRB) assay. NBQX (1,2,3,4-Tetrahydro-6-nitro-2,3-
dioxo-benzo[f]quinoxaline-7-sulfonamide disodium salt; Sigma-
Aldrich (St Louis, MO, USA)) was dissolved in H2O. Cells were
seeded in triplicate at 1610
4/ml (VU-122), 4610
4/ml (U87-MG)
in DMEM with 10% (U87-MG) and 20% FCS (VU-122) in 96-
well tissue culture plates (200 ml/well) and incubated with 6
concentrations of NBQX 21–82 mM. After 4 days of incubation
the cells were fixed with 30% trichloroacetic acid (TCA) (5 ml/
well) at 4uC for 1 hour. After four washes, TCA fixed cells were
stained with 0.4% SRB (100 ml/well) for 30 minutes, room
temperature. After three washes with 1% ethanoic acid, protein-
bound dye was dissolved in 10 mM Tris base (100 ml/well,
pH 10.5) and plates were analyzed at 540 nM using a Anthos
2001 plate reader (Anthos-Labtec, Cambridge, UK). Cell doubling
time was calculated based on proliferation curves resulting from
the change in SRB absorbance over time.
Supporting Information
Figure S1 In silico analysis of ionotropic glutamate receptor
expression levels in low grade astrocytomas and oligodendrogli-
omas. Boxplots of expression of ionotropic glutamate receptor
mRNA in a dataset of low grade gliomas - 50 oligodendrogliomas
(white), compared to 26 astrocytomas (grey dashed). None of the
GluR gene expression profiles showed major significance in
differential expression.
Found at: doi:10.1371/journal.pone.0005953.s001 (0.62 MB TIF)
Figure S2 Example traces after application of glutamate to lifted
GBM cells. 1000 mM of glutamate was ‘puffed’ during 100 ms to
GBM cell lines VU-028, VU-122 and U87-MG. In all cell lines
glutamate failed to evoke an inward current, whereas in a
pyramidal neuron, glutamate application evoked a large, inward,
quickly desensitizing current, mediated by AMPA receptor
AMPA Receptors in Glioblastoma
PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e5953activation. The trace is the average of 10–20 subsequent
applications.
Found at: doi:10.1371/journal.pone.0005953.s002 (0.16 MB TIF)
Figure S3 In silico analysis of transmembrane AMPAR
regulatory proteins (TARPs) expression levels in GBM tumors.
Expression of transmembrane AMPAR regulatory protein gamma
2 and 3 (TARP-c2 and TARP-c3) in a dataset of 77 glioblastomas
(grey dashed), compared to non-neoplastic, normal brain from
epilepsy surgery (white) (p,0.0001, t-test value 8.772 and 12.903
respectively).
Found at: doi:10.1371/journal.pone.0005953.s003 (0.25 MB TIF)
Table S1 In silico analysis using Oncomine [18], comparing
mRNA expression profiles in dataset of 77 GBMs with 23 samples
of non-neoplastic control brain tissue [19]. The t-test value
indicating effect size between the two classes, p-value reflecting
significance of the differential expression observed.
Found at: doi:10.1371/journal.pone.0005953.s004 (0.09 MB
RTF)
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